Recent study highlights the challenges in developing treatments for NASH

We previously commented on the failure of the ASK-1 inhibitor, selonsertib, in the STELLAR-4 phase III study in patients with compensated cirrhosis (F4) due to NASH.

Selonsertib has been tested in another study (STELLAR-3) in an earlier stage (F3) of NASH, where it has now been announced that also here, selonsertib failed to meet the primary endpoint of a ≥ 1-stage histologic improvement in fibrosis without worsening of NASH.

This is a disappointment to patients and the wider liver fibrosis community, and highlights the challenges in developing treatments for NASH. Reflecting on this result, presentations at the recent EASL meeting, and other observations, we believe that those aiming to develop a therapy in, or considering entering, the liver fibrosis area need to consider a number of factors, summarised in the diagram below.

We will be expanding on the above over the coming months but please contact us if you would like to learn more immediately.

We’d like to send you our company updates, invites to events and any other relevant news. By providing your details and subscribing to this list, you are giving us your consent to send you these updates.

We’ll always be mindful of how often we send our updates and you can amend your preferences at any time.

We’ll never sell or swap your data with any organisation and we’ll store your details securely, respecting your trust and privacy. Please view our privacy policy for further details.

Marketing Permissions
Please select all the ways you would like to hear from TherapeutAix:
You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.